verteporfin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
benzoporphyrin derivatives 2816 129497-78-5

Description:

MoleculeDescription

Synonyms:

  • verteporphin
  • verteporfin
  • trans-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester (1:1 mixture of two regioisomers)
  • visudyne
  • BPD-MA
A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION.
  • Molecular weight: 1437.61
  • Formula: C82H84N8O16
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 173.56
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 27, 2000 EMA
April 12, 2000 FDA VALEANT LUXEMBOURG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Visual acuity reduced 732.48 53.73 140 998 23270 90604039
Retinal haemorrhage 297.92 53.73 53 1085 5711 90621598
Choroidal neovascularisation 257.00 53.73 33 1105 374 90626935
Retinal pigment epithelial tear 188.93 53.73 24 1114 247 90627062
Polypoidal choroidal vasculopathy 169.49 53.73 19 1119 56 90627253
Subretinal fluid 111.69 53.73 17 1121 687 90626622
Disease progression 101.84 53.73 46 1092 156569 90470740
Retinal oedema 97.36 53.73 16 1122 1060 90626249
Detachment of retinal pigment epithelium 93.89 53.73 14 1124 491 90626818
Macular scar 78.30 53.73 10 1128 107 90627202
Retinal depigmentation 76.51 53.73 11 1127 298 90627011
Metamorphopsia 72.45 53.73 13 1125 1444 90625865
Vitreous haemorrhage 70.83 53.73 14 1124 2612 90624697
Maculopathy 65.41 53.73 13 1125 2493 90624816
Retinal pigment epitheliopathy 61.51 53.73 9 1129 276 90627033
Retinal degeneration 55.82 53.73 10 1128 1099 90626210

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Visual acuity reduced 1082.78 114.03 222 1405 17328 42602380
Retinal haemorrhage 783.15 114.03 142 1485 5628 42614080
Choroidal neovascularisation 387.96 114.03 52 1575 241 42619467
Polypoidal choroidal vasculopathy 359.88 114.03 46 1581 134 42619574
Detachment of retinal pigment epithelium 296.15 114.03 45 1582 565 42619143
Disease progression 269.43 114.03 123 1504 143533 42476175
Retinal pigment epithelial tear 266.45 114.03 38 1589 296 42619412
Vitreous haemorrhage 240.73 114.03 47 1580 2700 42617008
Retinal degeneration 159.55 114.03 27 1600 686 42619022
Retinal detachment 138.71 114.03 35 1592 6490 42613218
Subretinal fibrosis 132.48 114.03 18 1609 93 42619615
Macular oedema 132.25 114.03 30 1597 3539 42616169

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Visual acuity reduced 1756.03 58.73 341 2338 31832 110554788
Retinal haemorrhage 1005.38 58.73 177 2502 9324 110577296
Choroidal neovascularisation 668.45 58.73 86 2593 473 110586147
Polypoidal choroidal vasculopathy 530.55 58.73 64 2615 183 110586437
Disease progression 378.16 58.73 160 2519 243874 110342746
Detachment of retinal pigment epithelium 370.34 58.73 55 2624 950 110585670
Retinal pigment epithelial tear 358.43 58.73 49 2630 451 110586169
Vitreous haemorrhage 280.32 58.73 54 2625 4566 110582054
Subretinal fluid 216.57 58.73 36 2643 1308 110585312
Retinal oedema 196.10 58.73 34 2645 1593 110585027
Retinal degeneration 195.29 58.73 34 2645 1632 110584988
Retinal detachment 191.20 58.73 46 2633 11054 110575566
Subretinal fibrosis 171.13 58.73 23 2656 183 110586437
Macular oedema 168.28 58.73 38 2641 6928 110579692
Metamorphopsia 149.37 58.73 27 2652 1606 110585014
Retinal depigmentation 119.16 58.73 18 2661 348 110586272
Macular hole 107.14 58.73 19 2660 1012 110585608
Macular degeneration 100.25 58.73 32 2647 21627 110564993
Retinal pigment epitheliopathy 98.11 58.73 16 2663 514 110586106
Macular scar 97.92 58.73 13 2666 93 110586527
Maculopathy 92.32 58.73 20 2659 3007 110583613
Retinal disorder 91.36 58.73 19 2660 2351 110584269
Retinal exudates 90.25 58.73 17 2662 1267 110585353
Choroidal infarction 88.49 58.73 13 2666 206 110586414
Choroidal haemorrhage 74.09 58.73 11 2668 188 110586432
Retinal scar 71.34 58.73 12 2667 467 110586153
Visual field defect 64.06 58.73 19 2660 10053 110576567
Blindness 63.01 58.73 26 2653 36333 110550287

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01LA01 SENSORY ORGANS
OPHTHALMOLOGICALS
OCULAR VASCULAR DISORDER AGENTS
Antineovascularisation agents
FDA PE N0000009801 Photosensitizing Activity
FDA MoA N0000010217 Photoabsorption
FDA EPC N0000175540 Photoenhancer
MeSH PA D003879 Dermatologic Agents
MeSH PA D011838 Radiation-Sensitizing Agents
MeSH PA D017319 Photosensitizing Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:47868 photosensitizing agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:88230 autophagy inhibitor

Related Drugs by ATC class:

S01LA Antineovascularisation agents 7 drugs
afliberceptanecortavebevacizumabbrolucizumabfaricimabpegaptanibranibizumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Choroidal retinal neovascularization indication 75971007
Exudative age-related macular degeneration indication 414173003 DOID:10873
Ocular histoplasmosis syndrome indication 416770009
Pathologic Myopia indication
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4021216 VUID
N0000148662 NUI
D01162 KEGG_DRUG
4021216 VANDF
C0387288 UMLSCUI
CHEBI:32293 CHEBI
CHEMBL5314346 ChEMBL_ID
D000077362 MESH_DESCRIPTOR_UI
DB00460 DRUGBANK_ID
7145 INN_ID
0X9PA28K43 UNII
118886 RXNORM
31931 MMSL
8841 MMSL
d04533 MMSL
008219 NDDF
125708009 SNOMEDCT_US
387059006 SNOMEDCT_US
5362420 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Visudyne HUMAN PRESCRIPTION DRUG LABEL 1 0187-5600 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 26 sections
Visudyne HUMAN PRESCRIPTION DRUG LABEL 1 24208-560 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 25 sections